Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 2/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4690871 | 1.00 | KMT2A (0.53) | KMT2AALDH1A1GAAMEN1LMNA | |
| SCHEMBL4686780 | 0.90 | KMT2A (0.51) | KMT2AALDH1A1GAAMEN1LMNA | |
| SCHEMBL15061389 | 0.90 | KMT2A (0.53) | KMT2AALDH1A1GAAMEN1KDM4E | |
| SCHEMBL4686785 | 0.90 | KMT2A (0.51) | KMT2AALDH1A1GAAMEN1LMNA | |
| SCHEMBL4688586 | 0.90 | KMT2A (0.53) | KMT2AALDH1A1GAAMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL4692989 | 0.89 | KMT2A (0.52) | KMT2AALDH1A1GAAMEN1KDM4E | |
| SCHEMBL4689876 | 0.88 | ALDH1A1 (0.50) | KMT2AALDH1A1MEN1LMNAUCHL1 | |
| SCHEMBL4689873 | 0.88 | ALDH1A1 (0.50) | KMT2AALDH1A1MEN1LMNAUCHL1 | |
| SCHEMBL15061309 | 0.85 | KMT2A (0.64) | KMT2AALDH1A1GAAMEN1LMNA | |
| Hydrochloric Acid SCHEMBL4746838 | 0.84 | KMT2A (0.63) | KMT2AALDH1A1GAAMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476275-B2 | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-02 | — | — | US | claimed |
| US-8476275-B2 | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-1613596-B1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-7320979-B2 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | ABBOTT GMBH & CO. KG (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2006-07-20 | — | — | US | disclosed |
| EP-1613596-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089905-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | DRD2, DRD3, TACR1 | KMT2A 4228/4885ALDH1A1 1724/4885GAA 3322/4885 |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | PTGDR, TACR1, TACR2 | KMT2A 4198/4885ALDH1A1 1775/4885GAA 3515/4885 |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | CBR3, CNR2, CNR1 | KMT2A 4399/4885ALDH1A1 1505/4885GAA 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.